At a glance
ClinicalIndex Comparison RecordN/ACompleted· 57 enrolled
Drug / intervention
TrueTear™ +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Open-Label, Randomized, Proof of Concept Study Exploring Application of TrueTear™ for the Treatment of Meibomian Gland Disease
In Brief
A clinical study evaluating TrueTear™ and Thermalon Dry Eye Compress for Meibomian Glands and Dry Eye Syndromes. Completed, enrolled 57 participants across 1 site.
Detailed Summary
This study will compare the safety and efficacy of TrueTear™ to standardized moist heat compress (Thermalon® Dry Eye Compress) for the treatment of Meibomian Gland Disease (MGD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeibomian Glands, Dry Eye Syndromes
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartJul 2017
Primary CompletionDec 2017
TodayJul 2026
First PostedJul 24, 2017
Enrollment StartJul 26, 2017
Primary CompletionDec 12, 2017
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 8.9 years ago
Interventions
TrueTear™device
Intranasal application of TrueTear™ device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear™ per participant guide.
Thermalon Dry Eye Compressdevice
Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions.